Festinavir was licensed to Oncolys in 2006 from Yale University. About Bristol-Myers Squibb Bristol-Myers Squibb is normally a global biopharmaceutical company whose objective is to find, develop and deliver innovative medications that help individuals prevail over serious illnesses. About Oncolys BioPharma Oncolys BioPharma is a clinical-stage Japanese biotechnology organization whose mission is to serve individuals, and develop effective, innovative, and safe medicines through novel techniques with the purpose of treating people worldwide from cancer and severe infectious diseases. Oncolys BioPharma targets the development and partnering of not only HIV medication but also anti-hepatitis C and anti-cancer drugs.. Bristol-Myers Oncolys and Squibb BioPharma Enter Global Licensing Contract Bristol-Myers Squibb Company and Oncolys BioPharma Inc., a held biotechnology company located in Japan privately, have signed a definitive agreement under which Bristol-Myers Squibb shall acquire exceptional worldwide rights to manufacture, develop and commercialize festinavir, a once-a-day, orally obtainable nucleoside reverse transcriptase inhibitor in Stage II development for HIV.We’ve several marketing actions planned and you want to officially present the collection to the Swiss Market later in April, 2010. Our initial purchase of last week sold out in 2 days, so we are very excited. CEO Michael Arnkvarn stated, It is our intend to expand further in to the European Markets. We have a existence in Scandinavia and now Switzerland. We plan to open up at least 2 even more countries this full 12 months, and we expect Alphaderm Wellness and Body to be an integral partner in this expansion.